Risperdal Lawsuit: En Banc Hearing Denied: Pa. Superior Court
Risperdal Lawsuit: En Banc Hearing Denied: Pa. Superior Court
Introduction
Defendants named in the Risperdal lawsuit, Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, had filed a motion early March requesting a rehearing before the entire Pennsylvania Superior Court for reconsideration of a related January 2018 ruling. On March 16, 2018, the Pennsylvania Superior Court turned down this request.
As per the January 2018 court decision, the court allowed the plaintiff involved in the lawsuit to pursue punitive damages; this decision came after a three-judge panel found that the trial court should have considered the law of plaintiffs’ home states when considering whether or not punitive damages should be allowed. Anticipating thousands of plaintiffs seeking similar awards, the defendants filed a motion to oppose the decision.
Latest News
Study Links Roundup Chemical to Long-Term Brain Damage
A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…